JP6185932B2 - 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 - Google Patents

免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 Download PDF

Info

Publication number
JP6185932B2
JP6185932B2 JP2014552287A JP2014552287A JP6185932B2 JP 6185932 B2 JP6185932 B2 JP 6185932B2 JP 2014552287 A JP2014552287 A JP 2014552287A JP 2014552287 A JP2014552287 A JP 2014552287A JP 6185932 B2 JP6185932 B2 JP 6185932B2
Authority
JP
Japan
Prior art keywords
hpv
peptide
virus
coat
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014552287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504897A (ja
JP2015504897A5 (enExample
Inventor
ブライス チャカリアン，
ブライス チャカリアン，
デイヴィッド ピーボディ，
デイヴィッド ピーボディ，
エベネーザー タブマン，
エベネーザー タブマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM filed Critical STC UNM
Publication of JP2015504897A publication Critical patent/JP2015504897A/ja
Publication of JP2015504897A5 publication Critical patent/JP2015504897A5/ja
Application granted granted Critical
Publication of JP6185932B2 publication Critical patent/JP6185932B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014552287A 2012-01-12 2013-01-10 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法 Expired - Fee Related JP6185932B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585839P 2012-01-12 2012-01-12
US61/585,839 2012-01-12
PCT/US2013/020960 WO2013106525A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Publications (3)

Publication Number Publication Date
JP2015504897A JP2015504897A (ja) 2015-02-16
JP2015504897A5 JP2015504897A5 (enExample) 2016-03-03
JP6185932B2 true JP6185932B2 (ja) 2017-08-23

Family

ID=48781889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552287A Expired - Fee Related JP6185932B2 (ja) 2012-01-12 2013-01-10 免疫原性のｈｐｖのｌ２を含むｖｌｐ並びに関連する組成物及び方法

Country Status (8)

Country Link
EP (1) EP2802349B1 (enExample)
JP (1) JP6185932B2 (enExample)
CN (1) CN104159606A (enExample)
AU (1) AU2013207962B2 (enExample)
BR (1) BR112014017242A8 (enExample)
CA (1) CA2861021A1 (enExample)
HK (1) HK1203837A1 (enExample)
WO (1) WO2013106525A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9943580B2 (en) 2013-09-12 2018-04-17 Stc.Unm Malaria vaccine
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
JP6916209B2 (ja) * 2016-05-13 2021-08-11 フラッシュ セラピューティクス 特に免疫応答に関与する細胞への、ｒｎａの転移のためのウイルス粒子
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3076631A1 (en) 2017-09-29 2019-04-04 Deutsches Krebsforschungszentrum Cutaneous papilloma virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US20090028886A1 (en) * 2004-08-04 2009-01-29 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Also Published As

Publication number Publication date
BR112014017242A8 (pt) 2017-07-04
AU2013207962B2 (en) 2017-07-20
WO2013106525A1 (en) 2013-07-18
EP2802349A1 (en) 2014-11-19
AU2013207962A1 (en) 2014-08-07
EP2802349A4 (en) 2015-08-26
EP2802349B1 (en) 2017-12-06
HK1203837A1 (en) 2015-11-06
CN104159606A (zh) 2014-11-19
CA2861021A1 (en) 2013-07-18
JP2015504897A (ja) 2015-02-16
BR112014017242A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
AU2013207962B2 (en) Immunogenic HPV L2-containing VLPs and related compositions and methods
Tumban et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2
Pineo et al. Immunogenic assessment of plant‐produced human papillomavirus type 16 L1/L2 chimaeras
HK1244695A1 (zh) Hpv颗粒及其用途
US9884107B2 (en) Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
CN101343315B (zh) 截短的人乳头瘤病毒6型l1蛋白
US20170096456A1 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
Yang et al. Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus
Wang et al. Combined truncations at both N-and C-terminus of human papillomavirus type 58 L1 enhanced the yield of virus-like particles produced in a baculovirus system
US9717783B2 (en) Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
Motavalli Khiavi et al. A Dual‐Type L2 11‐88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross‐Reactive Antibodies in Vaccinated Mice
WO2016026401A1 (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
Villa Vaccines against papillomavirus infections and disease
Liu et al. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
WO2008082719A2 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101115766B (zh) 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
García-Carrancá Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer
Shokri et al. Designing of DNA vaccine based on a secretory form of major capsid protein of human papillomavirus type 18
RU2852174C1 (ru) Рекомбинантная вакцина против вируса гриппа а человека и способ ее получения
Yadav Efficacy of Mixed MS2-L2 VLPs against Six HPV Types and the Development & Evaluation of Viral Structural Proteins for Assembly into VLPs
Tornesello et al. Virus‑like particles as preventive and therapeutic cancer vac‑cines. Vaccines. 2022; 10: 227
JP6916115B2 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
Naupu The Immunogenicity of Plant-produced Human Papillomavirus (HPV) Virus-like particles (VLPs) in Mice
Kazaks et al. 11 Papillomavirus-Derived Virus-Like Particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170728

R150 Certificate of patent or registration of utility model

Ref document number: 6185932

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees